Editas Medicine Inc
EDIT
NASDAQ
Biotechnology
$2.82
USD
+0.01 (+0.36%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $441.54M
Volume 1.5M
Revenue
$47.01M
TTM
+20.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-73.95M
TTM
+68.8%
YoY
Operating Cash Flow
$-119.86M
TTM
+40.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 3.6 | 7.5 | 24.7 | 2.8 | 11.9 |
YoY Growth | +597.5% | +12265.6% | -19.2% | -39.2% | +232.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 3.6 | 7.5 | 24.7 | 2.8 | 11.9 |
Selling, General & Administrative | 12.9 | 12.3 | 11.4 | 10.2 | 11.6 |
Other Operating Expenses | 26.1 | 0.0 | -6.3 | 0.0 | -1.3 |
Total Operating Expenses | 55.1 | 32.1 | 32.5 | 27.8 | 30.4 |
Operating Income | -51.5 | -24.5 | -7.8 | -25.0 | -18.6 |
EBITDA | -23.6 | -23.8 | -13.2 | -24.5 | -19.5 |
Other Income / Expense | -1.8 | -0.0 | -0.0 | -0.1 | 0.0 |
Total Other Income / Expense | -1.7 | -0.6 | 2.1 | 0.0 | 0.3 |
Income Before Income Taxes | -53.2 | -25.1 | -5.6 | -25.0 | -18.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -53.2 | -25.1 | -5.6 | -25.0 | -18.2 |
Consolidated Net Income / Loss | -53.2 | -25.1 | -5.6 | -25.0 | -18.2 |
Net Income Attributable to Common Shareholders | -53.2 | -25.1 | -5.6 | -25.0 | -18.2 |
Basic EPS | -$0.63 | -$0.28 | -$0.06 | -$0.26 | -$0.15 |
Diluted EPS | -$0.63 | -$0.28 | -$0.06 | -$0.26 | -$0.15 |
Basic Shares Outstanding | 84.4M | 90.1M | 97.4M | 97.9M | 119.3M |
Diluted Shares Outstanding | 84.4M | 90.1M | 97.4M | 97.9M | 119.3M |